Leap Therapeutics Inc (LPTX) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Leap Therapeutics Inc (Leap Therapeutics), formerly HealthCare Pharmaceuticals Inc, is a clinical-stage biopharmaceutical company that develops novel therapeutics to treat patients with cancer. The companys pipeline products include DKN-01, a humanized monoclonal antibody that targets the Dickkopf-1 (DKK-1) protein, intended for the treatment of gastroesophageal cancer, biliary tract cancer, hepatocellular carcinoma, and non-small cell lung cancer; and TRX518, is a humanized anti-GITR (glucocorticoid-induced tumor necrosis factor receptor) monoclonal antibody that enhances the immune systems anti-tumor response and is in Phase 1 clinical trials intended for the treatment of solid tumors. Leap Therapeutics is headquartered in Cambridge, Massachusetts, the US.

Leap Therapeutics Inc (LPTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Leap Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Leap Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
GITR Raises US$3.25 Million In Seed Financing 12
Partnerships 13
Leap Therapeutics Enters into Immunotherapy Agreement with European Organisation for Research and Treatment of Cancer 13
Leap Therapeutics Enters into Agreement with Merck International 14
Merger 15
GITR Merges with HealthCare Pharmaceuticals to Form Leap Therapeutics 15
Equity Offering 16
Leap Therapeutics Raises USD16.1 Million in Public Offering of Shares 16
Leap Therapeutics Plans to Raise Funds in Secondary Offering of Shares 18
Leap Therapeutics to Raise USD18 Million in Private Placement of Units 19
Macrocure Completes IPO for USD54 Million 20
Acquisition 22
Leap Therapeutics Acquires Macrocure 22
Leap Therapeutics Inc - Key Competitors 24
Leap Therapeutics Inc - Key Employees 25
Leap Therapeutics Inc - Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Financial Announcements 27
May 11, 2018: Leap Therapeutics Reports First Quarter 2018 Financial Results 27
Feb 23, 2018: Leap Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results 29
Nov 13, 2017: Leap Therapeutics Reports Third Quarter 2017 Financial Results 31
Aug 11, 2017: Leap Therapeutics Reports Second Quarter 2017 Financial Results 32
May 12, 2017: Leap Therapeutics Reports First Quarter 2017 Financial Results 33
May 12, 2017: Leap Therapeutics Q1 net loss increases 34
Mar 31, 2017: Leap Therapeutics Reports Full Year 2016 Financial Results and Progression-Free Survival Data in Advanced Biliary Tract Cancers 35
Product News 37
04/16/2018: Leap Therapeutics Presents Nonclinical and Clinical Data on DKN-01 at AACR 2018 Annual Meeting 37
03/01/2017: Leap Therapeutics to Present Clinical Data on TRX518 at 2017 AACR Annual Meeting 38
03/01/2017: Leap Therapeutics to Present Data on DKN-01 at 2017 AACR Annual Meeting 39
02/03/2017: Leap Therapeutics Presents Biomarker and Efficacy Data at the Cholangiocarcinoma Foundation 2017 Annual Meeting 40
01/19/2017: Leap Therapeutics Presents Biomarker Data from Clinical Study of DKN-01 in Combination with Paclitaxel in Esophageal Cancer 41
Clinical Trials 42
Mar 14, 2018: Leap Therapeutics Provides DKN-01 Program Update and Announces Scientific Presentations at AACR Annual Meeting 42
Jan 16, 2018: Leap Therapeutics Announces First Patient Dosed with TRX518 Combination Therapy in Advanced Solid Tumors Trial 44
Nov 13, 2017: Leap Therapeutics Announces First Patient Dosed with DKN-01 and KEYTRUDA (pembrolizumab) in Esophagogastric Cancer Trial 45
Nov 13, 2017: Leap Therapeutics Provides Update on its Antineoplastic Drug Candidate TRX-518 46
May 17, 2017: Leap Therapeutics Presents Positive DKN-01 Clinical Data in Biliary Tract Cancers at American Society of Clinical Oncology 2017 Annual Meeting 47
May 12, 2017: Leap Therapeutics Provides Update on DKN-01 48
Apr 20, 2017: Leap Therapeutics to Present DKN-01 Clinical Data at American Society of Clinical Oncology 2017 Annual Meeting 49
Apr 03, 2017: Leap Therapeutics Presents Data on DKN-01 at the 2017 AACR Annual Meeting 50
Apr 03, 2017: Leap Therapeutics Presents Non-clinical and Phase 1 Data for TRX518 at the 2017 AACR Annual Meeting 51
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52

List Of Tables

List of Tables
Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Leap Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Leap Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Leap Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
GITR Raises US$3.25 Million In Seed Financing 12
Leap Therapeutics Enters into Immunotherapy Agreement with European Organisation for Research and Treatment of Cancer 13
Leap Therapeutics Enters into Agreement with Merck International 14
GITR Merges with HealthCare Pharmaceuticals to Form Leap Therapeutics 15
Leap Therapeutics Raises USD16.1 Million in Public Offering of Shares 16
Leap Therapeutics Plans to Raise Funds in Secondary Offering of Shares 18
Leap Therapeutics to Raise USD18 Million in Private Placement of Units 19
Macrocure Completes IPO for USD54 Million 20
Leap Therapeutics Acquires Macrocure 22
Leap Therapeutics Inc, Key Competitors 24
Leap Therapeutics Inc, Key Employees 25
Leap Therapeutics Inc, Subsidiaries 26

List Of Figures

List of Figures
Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Leap Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Leap Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Leap Therapeutics Inc (LPTX) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Leap Therapeutics Inc (Leap Therapeutics), formerly HealthCare Pharmaceuticals Inc, is a clinical-stage biopharmaceutical company that develops novel therapeutics to treat patients with cancer. The companys pipeline products include DKN-01, a

USD 250 View Report

Leap Therapeutics Inc (LPTX) - Medical Equipment - Deals and Alliances Profile

Leap Therapeutics Inc (Leap Therapeutics), formerly HealthCare Pharmaceuticals Inc, is a clinical-stage biopharmaceutical company that develops novel therapeutics to treat patients with cancer. The companys pipeline products include DKN-01, a

USD 250 View Report

Juno Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Juno Therapeutics Inc (Juno) is a clinical-stage company that develops novel cellular immunotherapies. The company formulates cell-based cancer immunotherapies based on platforms such as chimeric antigen receptor and high-affinity T

USD 250 View Report

Aquestive Therapeutics Inc (AQST) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Aquestive Therapeutics Inc (Aquestive Therapeutics) is a pharmaceutical company that discovers, develops and commercializes prescription drug products and a pipeline of prescription formulations. The company offers PharmFilm a drug delivery

USD 250 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available